Intellia Therapeutics’ (NTLA) Sell Rating Reiterated at The Goldman Sachs Group

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “sell” rating restated by equities researchers at The Goldman Sachs Group in a research note issued to investors on Friday. They currently have a $9.00 price objective on the stock. The Goldman Sachs Group’s target price would indicate a potential downside of 17.13% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Barclays decreased their price target on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. William Blair reaffirmed a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research note on Monday, November 18th. Wedbush restated a “neutral” rating and issued a $10.00 target price (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $90.00 price target on shares of Intellia Therapeutics in a report on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $46.06.

Intellia Therapeutics Stock Performance

Shares of Intellia Therapeutics stock opened at $10.86 on Friday. The company has a 50-day simple moving average of $10.90 and a two-hundred day simple moving average of $15.72. Intellia Therapeutics has a one year low of $8.96 and a one year high of $34.87. The company has a market capitalization of $1.11 billion, a PE ratio of -2.00 and a beta of 1.80.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last three months, insiders sold 29,000 shares of company stock valued at $352,551. Company insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new position in shares of Intellia Therapeutics in the 4th quarter valued at approximately $25,000. Sterling Capital Management LLC raised its holdings in Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after acquiring an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC bought a new position in Intellia Therapeutics during the 4th quarter valued at $40,000. Resona Asset Management Co. Ltd. bought a new stake in shares of Intellia Therapeutics in the 4th quarter worth about $43,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after purchasing an additional 794 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.